Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.98M | $6.30M | $4.04M | $2.27M | $2.84M | $5.11M | $7.02M | $7.75M | $6.93M | $5.94M |
| Revenue growth | — | 111.8% | -35.8% | -43.9% | 25.1% | 80.3% | 37.3% | 10.5% | -10.6% | -14.3% |
| Gross profit | $2.25M | $3.06M | -$120K | -$194K | $2.04M | $3.44M | $4.58M | $1.43M | $5.64M | $4.56M |
| Gross margin | 75.5% | 48.6% | -3.0% | -8.5% | 72.0% | 67.3% | 65.2% | 18.5% | 81.4% | 76.9% |
| Operating income | -$4.20M | -$4.28M | $80.00 | -$1.07M | -$5.20M | -$4.94M | -$9.92M | -$8.83M | -$4.01M | -$6.83M |
| Operating margin | -141.2% | -67.8% | 0.0% | -47.1% | -183.4% | -96.6% | -141.4% | -113.8% | -57.9% | -115.0% |
| Net income | -$4.19M | -$4.28M | -$6.87M | -$14.6M | -$9.67M | -$5.07M | -$11.9M | -$8.52M | -$4.30M | -$7.16M |
| Net margin | -140.8% | -67.8% | -169.8% | -643.4% | -341.0% | -99.0% | -169.7% | -109.9% | -62.1% | -120.6% |
| EPS (diluted) | -$0.89 | -$0.76 | -$0.73 | -$8.21 | -$2.08 | -$0.65 | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.45M | -$2.47M | -$1.61M | -$1.85M | -$4.95M | -$8.98M | -$6.23M | -$3.79M | -$2.91M | -$4.67M |
| Capital expenditures | $53.0K | $166K | $52.1K | $28.8K | $35.6K | $42.0K | $82.0K | $1.00K | $13.0K | $12.0K |
| Free cash flow | -$4.50M | -$2.63M | -$1.67M | -$1.88M | -$4.99M | -$9.02M | -$6.31M | -$3.79M | -$2.93M | -$4.68M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.06M | $289K | $324K | $79.0K | $17.0M | $7.75M | $2.64M | $511K | $438K | $2.69M |
| Total assets | $17.3M | $16.1M | $11.7M | $2.50M | $22.5M | $17.8M | $11.3M | $4.52M | $8.62M | $8.30M |
| Total liabilities | $1.84M | $2.33M | $1.23M | $4.78M | $2.19M | $2.15M | $6.04M | $3.45M | $4.84M | $3.20M |
| Long-term debt | — | — | — | — | — | $0.00 | $327K | $189K | $44.8K | — |
| Shareholders' equity | $15.5M | $13.8M | $10.5M | -$2.29M | $20.3M | $15.6M | $5.30M | $1.06M | $3.77M | $5.11M |
| Retained earnings | -$62.8M | -$67.1M | -$75.1M | -$89.7M | -$99.5M | -$105M | -$116M | -$118M | -$129M | -$136M |
| Shares (wtd avg diluted) | 6.09M | 7.69M | 14.0M | 1.81M | 7.81M | 7.79M | 437K | 560K | 206K | 665K |
Every figure is extracted from BIO KEY INTERNATIONAL INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.